 | | PRD_002097 | | Name: | [[[(4S)-5-[[(2S)-1-[[(2S)-5-[[azaniumylidene(azanyl)methyl]amino]-1-oxidanylidene-pentan-2-yl]amino]-3-methyl-1-oxidanylidene-butan-2-yl]amino]-5-oxidanylidene-4-[[(2S)-1-oxidanyl-1-oxidanylidene-3-phenyl-propan-2-yl]carbamoylamino]pentyl]amino]-azanyl-methylidene]azanium | | Formula: | C27 H46 N10 O6 | | Description: | Acts as a reversible inhibitor of serine/cysteine proteases and some trypsin-like serine proteases. | | Definition date: | 2013-08-07 | | Last modified: | 2022-10-20 |
|
 | | PRD_002471 | | Name: | N-{3-[(prop-2-yn-1-yl)oxy]propanoyl}-D-phenylalanyl-N-[(3S)-6-carbamimidamido-2-oxohexan-3-yl]-L-phenylalaninamide | | Formula: | C31 H40 N6 O5 | | Definition date: | 2022-10-12 | | Last modified: | 2022-10-12 |
|
 | | PRD_002472 | | Name: | N-{3-[(prop-2-yn-1-yl)oxy]propanoyl}-D-phenylalanyl-N-[(3S)-6-(carbamoylamino)-2-oxohexan-3-yl]-L-phenylalaninamide | | Formula: | C31 H39 N5 O6 | | Definition date: | 2022-10-12 | | Last modified: | 2022-10-12 |
|
 | | PRD_002509 | | Name: | Colistin | | Formula: | C52 H98 N16 O13 | | Definition date: | 2022-09-14 | | Last modified: | 2022-09-14 |
|
 | | PRD_002370 | | Name: | Taltirelin | | Formula: | C17 H24 N7 O5 | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002371 | | Name: | Endogenous Peptide Agonist TRH | | Formula: | C16 H23 N6 O4 | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002386 | | Name: | tert-butyl N-[3-(2-hydroxyethylcarbamoyl)-5-phenyl-thiophen-2-yl]carbamate | | Formula: | C18 H22 N2 O4 S | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002490 | | Name: | Eptifibatide | | Formula: | C35 H49 N11 O9 S2 | | Definition date: | 2022-08-17 | | Last modified: | 2022-08-17 |
|
 | | PRD_002496 | | Name: | evybactin | | Formula: | C64 H91 N21 O21 | | Definition date: | 2022-08-17 | | Last modified: | 2022-08-17 |
|
 | | PRD_002491 | | Name: | Sa-D2 | | Formula: | C88 H122 N19 O23 S2 | | Definition date: | 2022-08-10 | | Last modified: | 2022-08-10 |
|
 | | PRD_002492 | | Name: | Sa-D3 | | Formula: | C87 H110 N18 O24 S | | Definition date: | 2022-08-10 | | Last modified: | 2022-08-10 |
|
 | | PRD_002384 | | Formula: | C58 H95 N15 O15 | | Definition date: | 2022-08-03 | | Last modified: | 2022-08-03 |
|
 | | PRD_002495 | | Name: | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | | Formula: | C21 H31 N3 O8 S | | Definition date: | 2022-05-04 | | Last modified: | 2022-05-04 |
|
 | | PRD_000468 | | Name: | Allosamidin | | Formula: | C25 H42 N4 O14 | | Definition date: | 2015-07-18 | | Last modified: | 2022-03-03 |
|
 | | PRD_002479 | | Name: | Cyclic Peptide Inhibitor ZO1-GLN-SER-TPO-45W-MLL | | Formula: | C34 H48 F3 N6 O14 P | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002486 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[([1,1'-biphenyl]-4-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C49 H67 N5 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002487 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[(1H-indol-3-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C45 H64 N6 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_000323 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-[(1S,2R,3R)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-N~4~-[2-(d
imethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C34 H53 N5 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000353 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-{(1S,2S)-1-(cyclohexylmethyl)-2-hydroxy-2-[(3R)-1,5,5-trimethyl-2-oxopyrrolidin-3-yl]ethyl}-N~4~-[2-(dimethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C36 H54 N6 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000204 | | Name: | Vancomycin | | Formula: | C66 H75 Cl2 N9 O24 | | Description: | VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2022-01-06 |
|
 | | PRD_002455 | | Name: | D-PMI-omega | | Formula: | C82 H115 Cl N17 O20 | | Definition date: | 2021-11-17 | | Last modified: | 2021-11-17 |
|
 | | PRD_002454 | | Name: | Substrate-like cysteine protease inhibitor | | Formula: | C46 H70 Cl N10 O9 | | Definition date: | 2021-09-01 | | Last modified: | 2021-09-01 |
|
 | | PRD_002469 | | Name: | Inhibitor 18 | | Formula: | C30 H42 N4 O6 | | Definition date: | 2021-08-25 | | Last modified: | 2021-08-25 |
|
 | | PRD_002457 | | Name: | beta-D-glucopyranose-(1-4)-beta-D-glucopyranose-(1-3)-2-deoxy-2-fluoro-alpha-D-glucopyranose | | Formula: | C18 H31 F O15 | | Definition date: | 2021-05-19 | | Last modified: | 2021-05-19 |
|
 | | PRD_002377 | | Name: | (12S,15S)-N-[(2-fluorophenyl)methyl]-10,13-dioxo-12-{2-oxo-2-[(2R)-2-phenylpyrrolidin-1-yl]ethyl}-2-oxa-11,14-diazatricyclo[15.2.2.1~3,7~]docosa-1(19),3(22),4,6,17,20-hexaene-15-carboxamide | | Formula: | C39 H39 F N4 O5 | | Definition date: | 2021-04-28 | | Last modified: | 2021-04-28 |
|
